Localization of vectors and other agents
Methods are disclosed to enhance controlled localization and/or release of an agent at an anatomical and/or physiological site where the agent is desirable. In one embodiment, the method localizes vector transfected with a gene(s) that enhances neovascularization (i.e., genes encoding angiogenic agents). In another embodiment, the method localizes genes that inhibit neovascularization (i.e., genes encoding antiangiogenic agents) at sites where new blood vessel growth is undesirable. The vector is provided in a biocompatible substance substantially preventing migration of the vector from the site in need of therapy. The substance may be a matrix, gel, a polymer, liposome, capsule, nanoparticle, microparticle. The substance may form in situ, for example, a fibrin entraining mesh or network form from fibrinogen and thrombin.
1 . A method of localizing gene therapy comprising providing at a body site in need of therapy a vector transfected with a gene encoding a therapeutic agent, the vector provided In a biocompatible substance substantially localizing the vector at the site in need of therapy.
2 . The method of claim 1 wherein the substance is at least one of a biocompatible matrix, a gel, a polymer, a liposome, a capsule, a nanoparticle, and/or a microparticle.
3 . The method of claim 1 wherein the substance forms in situ.
4 . The method of claim 1 wherein the vector is at least one of a virus or a plasmid.
5 . The method of claim 1 wherein the gene encodes an agent selected from the group consisting of an agent that enhances angiogenesis and an agent that enhances antiangiogenesis.
6 . The method of claim 1 wherein the gene encodes at least one of a vascular endothelial growth factor or a platelet derived growth factor.
7 . A method of localizing gene therapy comprising administering at an ocular site in need of therapy a composition comprising a gene encoding a desired agent, fibrinogen, and thrombin in concentrations sufficient to convert fibrinogen to form a fibrin network, the fibrin network entraining the gene at the site in need of therapy.
8 . (canceled)
9 . The method of claim 7 wherein the gene encodes at least one of an angiogenic agent or an antiangiogenic agent.
10 . The method of claim 7 wherein the gene encodes at least one of a vascular endothelial growth factor or a platelet derived growth factor.